Bharat Immunologicals & Biologicals share price
BSE: 524663Pharmaceuticals & BiotechnologySmall Cap
Last close ₹9.27up ₹0.09 (0.98%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹9.18.
52-week range of traded prices to 23 Oct 2026
₹7.11Low, 6 Oct 2026₹22.61High, 23 Dec 2025
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- Share count not known3,103rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Share count not known
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Share count not known
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- –
- Volume, BSEVolume. Shares traded on the last trading day.
- 28,767
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter. No standalone results on record for the years to Mar 2012, Mar 2013, Mar 2014, Mar 2015 and Mar 2016.Quarterly results
Quarter to Dec 2022, against the quarter beforeFiled 16 Feb
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.00 Crdown 100.00%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹4.68 CrQuarter to Sep 2022: −₹3.08 Cr
Revenue by year
Peak revenue ₹124 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 5 years with results on record
| ₹ crore | Jun 2021Filed 30 Jul | Sep 2021Filed 2 Nov | Dec 2021Filed 16 Feb | Mar 2022 | Jun 2022Filed 17 Nov | Sep 2022Filed 17 Nov | Dec 2022Filed 16 Feb |
|---|---|---|---|---|---|---|---|
| Revenue | 14.2 | 24.7 | 17.4 | – | 10.5 | 26.5 | 0.0 |
| Net profit | 1.9 | −9.4 | −0.7 | – | −5.0 | −3.1 | −4.7 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 13.6% | −37.9% | −3.8% | – | −47.7% | −11.6% | – |
Standalone. The last eight quarters. The latest is shaded. No results on record for the quarters to Mar 2021 and Mar 2022.
Business segments
Share of revenue, year to Mar 2019, standalone.Segment revenue and profit
- ORAL POLIO VACCINEORAL POLIO VACCINE, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹83.6 Cr99.9%
- ZINC DISPERSIBLE TABLETSZINC DISPERSIBLE TABLETS, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹0.1 Cr0.1%
- BIB SWEETS TABLETSBIB SWEETS TABLETS, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹0.0 Cr0.0%
Where the return came from
Yearly rates to Mar 2019, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −61.0% | – | – | 0.0% |
| 3 years | −25.3% | – | – | 0.0% |
| 5 years | −2.4% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Bharat Immunologicals & Biologicals in market cap. 4 companies in the table last traded before then: their rows are priced on their last trade.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | – | 0.00% |
 Adline Chem LabADLINE | 9 | – | – | – | – | – | – | −685.2% | 0.00% |
 Brawn BiotechBRAWN | 8 | 8.9 | 1.8 | – | +13.6% | – | 22.3% | −12.6% | 0.00% |
 Vivanza BiosciencesVIVANZA | 6 | 14.1 | 1.5 | 32.8 | +735.0% | – | 10.9% | 3.3% | 0.00% |
 Decipher LabsDECIPHER | 5 | – | 0.6 | – | −25.2% | – | – | −31.5% | 0.00% |
 Advik LaboratoriesADVIKLA | 4 | – | 58.0 | – | – | – | −180.6% | −14.5% | 0.00% |
 Shyama Computronics and ServicesSHYAMACOMP | 4 | – | 0.4 | 58.5 | +9.4% | – | – | 0.6% | 0.00% |
 Gujarat Inject (Kerala)GUJINJEC | – | – | – | – | +151.6% | +209.0% | 27.4% | 32.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
30 Sep · Legal
Exchange has sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd on September 30, 2026 with reference to significant movement in price, in order to ensure ....17 Sep · Announcement under Regulation 30 (LODR)-Winding-up
Aug 2024
7 Aug · Board meeting
Meeting on 16 Aug 2024
Feb 2024
29 Feb · Board meeting
Meeting on 8 Mar 2024
Bharat Immunologicals & Biologicals share price by year
Each calendar year to 2025.Bharat Immunologicals & Biologicals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 20.07 | −15.5% | 32.33 | 18.27 |
| 2024 | 23.74 | −32.8% | 40.44 | 23.06 |
| 2023 | 35.35 | −11.4% | 40.70 | 21.19 |
| 2022 | 39.90 | −31.7% | 56.60 | 22.70 |
| 2021 | 58.45 | +15.1% | 90.00 | 38.15 |
| 2020 | 50.80 | +588.3% | 50.80 | 5.69 |
| 2019 | 7.38 | −37.8% | 12.18 | 5.65 |
| 2018 | 11.86 | −65.6% | 36.95 | 11.63 |
| 2017 | 34.45 | +67.6% | 36.75 | 19.90 |
| 2016 | 20.55 | −33.0% | 32.15 | 16.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 9.49 | 9.49 | 8.90 | 9.27 | 9.24 | 28,767 |
| 22 Oct 2026 | 9.05 | 9.45 | 8.75 | 9.18 | 9.03 | 21,709 |
| 21 Oct 2026 | 9.90 | 9.90 | 8.81 | 9.05 | 9.15 | 21,586 |
| 19 Oct 2026 | 9.71 | 9.90 | 9.52 | 9.55 | 9.64 | 17,122 |
| 16 Oct 2026 | 9.89 | 10.17 | 9.40 | 9.91 | 9.72 | 46,920 |
| 15 Oct 2026 | 9.50 | 10.10 | 9.50 | 9.88 | 9.86 | 50,231 |
| 14 Oct 2026 | 9.69 | 9.79 | 9.27 | 9.56 | 9.65 | 16,792 |
| 13 Oct 2026 | 9.02 | 9.55 | 9.02 | 9.50 | 9.36 | 38,323 |
| 12 Oct 2026 | 8.99 | 9.25 | 8.82 | 9.02 | 9.07 | 38,577 |
| 9 Oct 2026 | 8.85 | 9.22 | 8.51 | 8.73 | 8.77 | 98,223 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 524663
- ISIN
- INE994B01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1994
- Face value
- ₹10
- CIN
- L24232UP1989GOI010542
- Corporate identity number, the registrar of companies' code for it